The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.
A user is experiencing severe hair loss, diagnosed with seborrheic dermatitis, and is using Ketoconazole and beclomethasone. They are concerned about potential female pattern baldness and are seeking reassurance and advice.
The conversation discusses new hair loss treatments like stem cell therapy, exosome treatments, and DHI, with mentions of GT20029, Amp303, and Plated PRP Serum as promising options. It also notes the use of dutasteride, topical finasteride, and minoxidil, but the focus is on non-hormonal innovations.
User shared 13 months of progress using finasteride, microneedling, vitamins, and scalp care, and recently started stemoxydine. The post includes before and after photos.
The conversation is about a 21-year-old male inquiring about the effectiveness of exosome therapy for hair thinning on the crown and considering whether to start Minoxidil while already on Finasteride and having had exosome injections 15 days ago.
Japanese scientists discovered ABM cells, enabling successful human hair follicle cloning, potentially curing hair loss. The treatment may be available in Japan by 2028, but it will be expensive and require travel.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
The conversation discusses the potential benefits and risks of participating in the PP405 hair loss trials, emphasizing that those using Minoxidil or finasteride are less likely to be accepted. Participants are interested in the trial as it offers hope for effective treatment without the side effects associated with current medications.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.